Results 11 to 20 of about 8,937,523 (396)

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

Journal of Clinical Oncology, 2021
PURPOSE: IMpower133 (ClinicalTrials.gov identifier: NCT02763579), a randomized, double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed death-ligand 1 [PD-L1]) to carboplatin plus etoposide (CP/ET) for first-line (1L ...
Stephen V. Liu, M. Reck, A. Mansfield, T. Mok, A. Scherpereel, N. Reinmuth, M. Garassino, J. de Castro Carpeño, R. Califano, M. Nishio, F. Orlandi, J. Alatorre-Alexander, T. Leal, Ying Cheng, Jong-Seok Lee, S. Lam, M. McCleland, Yu Deng, S. Phan, L. Horn   +19 more
semanticscholar   +1 more source

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer

European Urology Open Science, 2023
The PROpel trial assessed the combination of olaparib + abiraterone acetate (AA) plus prednisone and androgen deprivation therapy (ADT) versus AA plus prednisone and ADT alone as first-line treatment for metastatic castration-resistant prostate cancer ...
Giuseppe Fallara, Daniele Robesti, Daniele Raggi, Francesco Montorsi, Andrea Necchi, Matthew R. Cooperberg, Bernard Malavaud, Guillaume Ploussard, Alberto Martini   +8 more
doaj   +1 more source

A novel nomogram to predict the overall survival in esthesinoeroblastoma [PDF]

BMC Cancer, 2020
Abstract Background Increasing evidence indicates that the pathology and the modified Kadish system have some influence on the prognosis of esthesioneuroblastoma (ENB). However, an accurate system to combine pathology with a modified Kadish system has not been established.
Lijie Jiang, Tengjiao Lin, Yu Zhang, Wenxiang Gao, Jie Deng, Zhaofeng Xu, Xin Luo, Zhaoqi Huang, Fenghong Chen, Jianbo Shi, Yinyan Lai   +10 more
openaire   +3 more sources

Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.

New England Journal of Medicine, 2023
BACKGROUND Tebentafusp, a T-cell receptor-bispecific molecule that targets glycoprotein 100 and CD3, is approved for adult patients who are positive for HLA-A*02:01 and have unresectable or metastatic uveal melanoma.
Jessica C Hassel, S. Piperno-Neumann, Piotr Rutkowski, J.-F. Baurain, M. Schlaak, Marcus O. Butler, R.J. Sullivan, R. Dummer, John M. Kirkwood, M. Orloff, J.J. Sacco, S. Ochsenreither, A.M. Joshua, L. Gastaud, B. Curti, J. Piulats, April K.S. Salama, A. Shoushtari, Lev V. Demidov, Mohammed M Milhem, B. Chmielowski, Kevin B Kim, Richard D. Carvajal, O. Hamid, L. Collins, Koustubh Ranade, C. Holland, Constance Pfeiffer, P. Nathan   +28 more
semanticscholar   +1 more source

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.

New England Journal of Medicine, 2022
BACKGROUND In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole resulted in significantly longer progression-free survival than letrozole alone among postmenopausal patients with hormone receptor (HR)-positive, human ...
G. Hortobagyi, S. Stemmer, H. Burris, Y. Yap, G. Sonke, L. Hart, M. Campone, K. Petráková, E. Winer, W. Janni, P. Conte, D. Cameron, F. André, C. Arteaga, J. P. Zarate, A. Chakravartty, T. Taran, Fabienne Le Gac, P. Serra, J. O’Shaughnessy   +19 more
semanticscholar   +1 more source

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.

New England Journal of Medicine, 2021
BACKGROUND Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic uveal melanoma.
P. Nathan, J. Hassel, P. Rutkowski, J. Baurain, M. Butler, M. Schlaak, R. Sullivan, S. Ochsenreither, R. Dummer, J. Kirkwood, A. Joshua, J. Sacco, A. Shoushtari, M. Orloff, J. Piulats, M. Milhem, A. Salama, B. Curti, L. Demidov, L. Gastaud, C. Mauch, Melinda L. Yushak, R. Carvajal, O. Hamid, S. Abdullah, C. Holland, H. Goodall, S. Piperno-Neumann   +27 more
semanticscholar   +1 more source

The five-year survival of gastric cancer patients with a focus on its prognostic factors [PDF]

Journal of Preventive Epidemiology, 2022
Introduction: Despite extensive advances in the early diagnosis and treatment of gastric cancer, it is still one of the most common causes of death worldwide.
Abdolhassan Talaiezadeh, Mahsa Noroozi, Pedram Nazari, Ali Ehsanpour   +3 more
doaj   +1 more source

Osteosarcoma of the Pelvis: Clinical Presentation and Overall Survival [PDF]

Sarcoma, 2021
Introduction. Osteosarcoma is the most common sarcoma of bone. Pelvic osteosarcoma presents a significant therapeutic challenge due to potential late symptom onset, metastatic dissemination at diagnosis, and inherent difficulties of wide surgical resection secondary to the complex and critical anatomy of the pelvis.
Jeffrey Mark Brown, David Matichak, Kyla Rakoczy, John Groundland   +3 more
openaire   +2 more sources

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation

JAMA Oncology, 2021
Key Points Question Does ivosidenib treatment improve overall survival outcomes vs placebo among patients with chemotherapy-refractory cholangiocarcinoma with IDH1 mutation?
A. Zhu, T. Macarulla, M. Javle, R. Kelley, S. Lubner, J. Adeva, J. Cleary, D. Catenacci, M. Borad, J. Bridgewater, W. Harris, A. Murphy, D. Oh, J. Whisenant, M. Lowery, L. Goyal, R. Shroff, A. El-Khoueiry, Christina X. Chamberlain, E. Aguado-Fraile, S. Choe, Bin Wu, Hua Liu, C. Gliser, S. Pandya, J. Valle, G. Abou-Alfa   +26 more
semanticscholar   +1 more source

Factors associated with increased survival after surgical resection of glioblastoma in octogenarians. [PDF]

, 2015
Elderly patients with glioblastoma represent a clinical challenge for neurosurgeons and oncologists. The data available on outcomes of patients greater than 80 undergoing resection is limited.
Abdullah, Kalil G, Brem, Steven, Macyszyn, Lukasz, Martinez-Lage, Maria, O'Rourke, Donald M, Ramayya, Ashwin, Thawani, Jayesh P   +6 more
core   +6 more sources